EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Multizentrische StudieOpen Access · CC BY 4.0

Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy

Crystal M Proud, Richard S Finkel, Julie A Parsons, Riccardo Masson, John F Brandsema, Nancy L Kuntz, Richard Foster, Wenjing Li, Ross Littauer, Jihee Sohn, Stephanie Fradette, Bora Youn und 2 weitere

Journal of Clinical Investigation · 17.11.2025 · 135 (22)

DOI: 10.1172/jci193956 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Journal of Clinical Investigation, online erschienen am 16.09.2025. Verfasst von Crystal M Proud und 13 weiteren Autor:innen. Beteiligte Einrichtung: Neurology and Neuromuscular Medicine, Children's Hospital of The King's Daughters, Norfolk, Virginia, USA. Hauptthemen laut MEDLINE: Oligonucleotides, Muscular Atrophy, Spinal, Biological Products, Spinal Muscular Atrophies of Childhood. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biogen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disease caused by deletions or mutations of the survival motor neuron 1 ( SMN1 ) gene. Despite the availability of genetically based treatments for SMA, functional impairments and weakness persist in treated symptomatic individuals. This study addresses whether additional treatment after gene transfer therapy could provide further clinical benefits. METHODS Interim day 302 findings are described from the phase IV open-label RESPOND trial evaluating nusinersen in participants aged ≤36 months who had suboptimal clinical status following onasemnogene abeparvovec (OA) treatment, as determined by the investigator. RESULTS Thirty-seven participants included in the interim analysis were symptomatic at the time of OA administration. Most (92%) had 2 SMN2 gene copies. Age at first nusinersen dose (median) was 9.1 (range, 3–33) months for participants with 2 SMN2 copies and 34.2 (range, 31–36) months for those with 3 SMN2 copies, while time from OA dose to first nusinersen dose (median) was 6.3 (range, 3–31) and 13.3 (range, 10–22) months, respectively. Participants had elevated neurofilament light chain (NfL) levels and low compound muscle action potential (CMAP) amplitudes at baseline, suggesting active neurodegeneration and severe denervation at study entry. Improvements from baseline were observed across a range of outcomes on day 302, including motor function (HINE-2 and CHOP-INTEND total score), achievement of independent sitting, NfL levels, CMAP, and investigator- and caregiver-reported outcomes. Mean NfL levels decreased rapidly from baseline to day 183 and remained low on day 302. Mean ulnar and peroneal CMAP amplitudes increased. No safety concerns were identified. CONCLUSION Improvements in clinical and biomarker outcomes support the benefit of nusinersen treatment in infants and children with suboptimal clinical status following OA. TRIAL REGISTRATION ClinicalTrials.gov NCT04488133; EudraCT 2020-003492-18. FUNDING This study was sponsored by Biogen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligonucleotidesMuscular Atrophy, SpinalBiological ProductsSpinal Muscular Atrophies of ChildhoodHumansFemaleMaleInfantChild, PreschoolSurvival of Motor Neuron 2 ProteinSurvival of Motor Neuron 1 ProteinRecombinant Fusion Proteins

Stichwörter der Autor:innen

Clinical ResearchGene therapyMuscle biology

Substanzen

nusinersenOligonucleotidesSurvival of Motor Neuron 2 ProteinBiological ProductsSMN2 protein, humanZolgensmaSurvival of Motor Neuron 1 ProteinRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Neurology and Neuromuscular Medicine, Children's Hospital of The King's Daughters, Norfolk, Virginia, USA.
  • Center for Experimental Neurotherapeutics, Department of Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Neuroimmunology and Neuromuscular Disease Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Division of Neurology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.

Förderung

  • Biogen

Zitieren

APA

Proud, C. M., Finkel, R. S., Parsons, J. A., Masson, R., Brandsema, J. F., Kuntz, N. L., Foster, R., Li, W., Littauer, R., Sohn, J., Fradette, S., Youn, B., Paradis, A. D., & RESPOND Study Group (2025). Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy. Journal of Clinical Investigation, 135(22). https://doi.org/10.1172/jci193956

Vancouver

Proud CM, Finkel RS, Parsons JA, Masson R, Brandsema JF, Kuntz NL, et al. Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy. Journal of Clinical Investigation. 2025;135(22). doi:10.1172/jci193956

BibTeX
@article{Proud2025,
  author = {Proud, Crystal M and Finkel, Richard S and Parsons, Julie A and Masson, Riccardo and Brandsema, John F and Kuntz, Nancy L and Foster, Richard and Li, Wenjing and Littauer, Ross and Sohn, Jihee and Fradette, Stephanie and Youn, Bora and Paradis, Angela D and RESPOND Study Group, RESPOND Study Group},
  title = {Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  volume = {135},
  number = {22},
  doi = {10.1172/jci193956}
}
Kostenlos starten →